| CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ... Journal of the National Cancer Institute 97 (1), 30-39, 2005 | 1179 | 2005 |
| Clinical significance of the cytochrome P450 2C19 genetic polymorphism Z Desta, X Zhao, JG Shin, DA Flockhart Clinical pharmacokinetics 41, 913-958, 2002 | 1172 | 2002 |
| Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine V Stearns, MD Johnson, JM Rae, A Morocho, A Novielli, P Bhargava, ... Journal of the National Cancer Institute 95 (23), 1758-1764, 2003 | 1038 | 2003 |
| Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes MP Goetz, JM Rae, VJ Suman, SL Safgren, MM Ames, DW Visscher, ... Journal of Clinical Oncology 23 (36), 9312-9318, 2005 | 993 | 2005 |
| Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 Z Desta, BA Ward, NV Soukhova, DA Flockhart Journal of Pharmacology and Experimental Therapeutics 310 (3), 1062-1075, 2004 | 840 | 2004 |
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with … BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ... Journal of Clinical Oncology 26 (28), 4672-4678, 2008 | 724 | 2008 |
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate … BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003 | 715 | 2003 |
| The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen MP Goetz, SK Knox, VJ Suman, JM Rae, SL Safgren, MM Ames, ... Breast cancer research and treatment 101, 113-121, 2007 | 698 | 2007 |
| Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ... Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006 | 576 | 2006 |
| Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen MD Johnson, H Zuo, KH Lee, JP Trebley, JM Rae, RV Weatherman, ... Breast cancer research and treatment 85, 151-159, 2004 | 576 | 2004 |
| Drug interactions: cytochrome P450 drug interaction table DA Flockhart Indiana University School of Medicine 2010, 2007 | 552 | 2007 |
| Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3': 5'-monophosphate-dependent protein kinase. JD Corbin, PH Sugden, L West, DA Flockhart, TM Lincoln, D McCarthy The Journal of biological chemistry 253 (11), 3997-4003, 1978 | 546 | 1978 |
| Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges RA Wilke, DW Lin, DM Roden, PB Watkins, D Flockhart, I Zineh, ... Nature reviews Drug discovery 6 (11), 904-916, 2007 | 471 | 2007 |
| Regulatory mechanisms in the control of protein kinase DA Flockhart, JD Corbin Critical reviews in biochemistry 12 (2), 133-186, 1982 | 421 | 1982 |
| Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays JM Rae, MD Johnson, ME Lippman, DA Flockhart Journal of Pharmacology and Experimental Therapeutics 299 (3), 849-857, 2001 | 415 | 2001 |
| Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer NL Henry, F Azzouz, Z Desta, L Li, AT Nguyen, S Lemler, J Hayden, ... Journal of Clinical Oncology 30 (9), 936-942, 2012 | 388 | 2012 |
| Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen YC Lim, Z Desta, DA Flockhart, TC Skaar Cancer chemotherapy and pharmacology 55, 471-478, 2005 | 367 | 2005 |
| Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants JE Tanus-Santos, M Desai, DA Flockhart Pharmacogenetics and Genomics 11 (8), 719-725, 2001 | 362 | 2001 |
| Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications S Bernard, KA Neville, AT Nguyen, DA Flockhart The oncologist 11 (2), 126-135, 2006 | 339 | 2006 |
| Pharmacogenomics: challenges and opportunities DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ... Annals of internal medicine 145 (10), 749-757, 2006 | 306 | 2006 |
